Answers are grounded in this paper and cite their sources.
Multiple primary malignant tumors (MPMTs) are relatively rare among patients with malignancies, and the occurrence of five metachronous primary cancers in the same patient is even rarer. Here, we report a case of a 42-year-old female patient who was diagnosed with five metachronous MPMTs over a span of 13 years, in chronological order: right breast cancer (2013), right lung adenocarcinoma (2018), left ovarian mucinous adenocarcinoma (2024), gastric poorly cohesive carcinoma (2025), and left breast cancer (2026). Tumor tissue testing of the ovarian cancer revealed a classical pathogenic variant of TP53 (p.R273H). Combined with her clinical phenotype meeting the Chompret criteria, she was clinically suspected to have Li-Fraumeni syndrome (LFS); however, peripheral blood validation was not performed, so the germline status remains unconfirmed. Molecular profiling identified PIK3CA H1047L, PTEN R130Q, and E157* mutations in the ovarian cancer; an EGFR L858R mutation in the lung cancer; and HER2 positivity (IHC 3+) in the left breast cancer. This case highlights that in patients with early-onset breast cancer (particularly < 46 years of age) and those with multiple primary malignancies, a high index of suspicion for hereditary cancer predisposition syndromes should be maintained. Timely genetic testing, including comprehensive germline validation, is essential to enable individualized surveillance, treatment, and familial genetic counseling.
No takes yet. Share an insight, caveat, or question.
Ren et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: